Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097379
- Locations
- π³π±
Novartis Investigative Site, Leiden, Netherlands
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Phase 1
Completed
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Study of Out of Specification for Tisagenlecleucel
Phase 3
Recruiting
- Conditions
- B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT04094311
- Locations
- π―π΅
Novartis Investigative Site, Wakayama, Japan
Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04085653
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
Phase 4
Completed
- Conditions
- Migraine HeadacheMigraineMigraine Disorders
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 701
- Registration Number
- NCT04084314
- Locations
- π©πͺ
Novartis Investigative Site, Wuerzburg, Germany
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04079231
Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT04074590
- Locations
- πΈπ°
Novartis Investigative Site, Kosice, Slovakia
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 974
- Registration Number
- NCT04072887
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT04072302
- Locations
- πΊπΈ
Novartis Investigative Site, Seattle, Washington, United States
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT04066244
- Locations
- πΊπΈ
Yale University School of Medicine, New Haven, Connecticut, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΈπͺNovartis Investigative Site, Stockholm, Sweden
Β© Copyright 2025. All Rights Reserved by MedPath